The Service Line

A sham-controlled trial found that catheter ablation for atrial fibrillation does not improve quality of life more than a fake procedure, a direct challenge to cardiology’s fastest-growing procedure. PVI-SHAM-AF, a randomized, double-blind trial of 262 patients, was presented in a Hot Line session at the European Society of Cardiology (ESC) Congress on August 30, 2026, and published simultaneously in The Lancet. Patients were randomized 2 to 1 to catheter ablation or a sham procedure. Ablation cut atrial fibrillation (AFib) recurrence sharply, 73 percent free of AFib at six months versus 52 percent for sham, but the AFib-specific quality-of-life score improved almost identically in both arms (61.3 to 81.1 for ablation, 59.2 to 74.9 for sham), a difference the investigators called not statistically significant. Lead investigator Rolf Wachter of the University of Leipzig said most of the quality-of-life gain patients attribute to ablation likely reflects a placebo effect or other factors rather than the procedure itself. AFib ablation (Current Procedural Terminology code 93656) is the highest-growth procedure in electrophysiology and the engine behind the specialty’s pulsed field ablation buildout; a credible, peer-reviewed challenge to its symptom benefit, even with the recurrence advantage intact, gives payers new language for future coverage reviews. Confidence: High on the trial results; Medium on how quickly this changes payer policy or referral volume. ESC press release.

Reimbursement

The American College of Cardiology’s comment letter on the 2027 hospital outpatient rule asks CMS to raise cardiac PET/CT payment and drop a proposed site-neutral cut to office imaging. The American College of Cardiology (ACC) filed its formal comments on the Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) proposed rule ahead of the August 31, 2026 comment deadline, backing higher reimbursement for cardiac positron emission tomography and computed tomography (PET/CT), continued protection for cardiac CT angiography payment, and opposing a proposed site-neutral cut to off-campus imaging. The underlying rule would remove roughly 637 more procedures from Medicare’s inpatient-only list as part of a three-year phase-out, with several cardiovascular-specific procedures, including percutaneous coronary intervention drug-eluting stent codes and cardiac contractility modulation systems, getting new Ambulatory Payment Classification assignments. The Centers for Medicare and Medicaid Services (CMS) is not required to finalize the rule until November, so nothing changes yet, but the comment record is now what the agency has to answer. Confidence: High on the letter and the rule’s provisions; Medium on which asks CMS adopts. ACC comment letter announcement · CMS CY2027 OPPS/ASC fact sheet.

Enforcement

No new cardiology-specific enforcement action broke this window; the live audit thread is still the one the Department of Health and Human Services Office of Inspector General (OIG) opened in May. OIG’s finding that Medicare Part B paid more than one billion dollars in 2022 for office-based peripheral vascular procedures, angioplasty, stenting, and atherectomy, remains the operative program-integrity signal for the specialty. It is the framework that preceded the $6.73 million vascular practice settlement we covered last cycle, and it is the screen Medicare Administrative Contractors are expected to keep pulling audit targets from. Confidence: High. OIG peripheral vascular utilization report.

Who’s Buying

Medtronic’s completed purchase of cath-lab imaging AI maker CathWorks points to a consolidation vector outside the private-equity roll-up story: device makers buying the software that reads the angiogram. Medtronic closed its acquisition of CathWorks, valued at up to $585 million, on April 20, 2026. CathWorks makes the FFRangio system, which computes fractional flow reserve, a measure of how much a blockage restricts blood flow, directly from standard angiogram images instead of requiring a pressure wire threaded into the artery; Medtronic folded it into its coronary and renal denervation business. Alongside the roughly 50 percent of cardiology practices already private-equity owned and the hospital-employment and payer-partnership tracks we have covered, this is a fourth consolidation vector worth watching: device makers acquiring the intelligence layer that sits inside the cath lab rather than the practices themselves. Confidence: High on the deal terms; Medium on how quickly this pattern repeats with other device makers. Medtronic acquisition completion announcement.

Clinical Policy

CMS’s mandatory heart-failure payment model roster is final, and the American College of Cardiology says roughly one in five cardiologists on it does not belong there. CMS has published its list of 2,600 general cardiologists required to join the Ambulatory Specialty Model (ASM) for heart failure when it launches January 1, 2027, confirming the specialty-misclassification risk ACC first flagged in July. ACC’s review found about 500 of the listed physicians, including electrophysiologists, interventional cardiologists, and advanced heart-failure and transplant specialists, were added in error because the model is meant to apply only to general cardiology. ACC is urging affected physicians to contact CMS directly and correct their Medicare enrollment (PECOS or CMS-855) before the roster locks for the launch. Confidence: High on the roster and misclassification figures; Medium on whether CMS corrects the list before launch. ACC on the misclassification risk · CMS Ambulatory Specialty Model page.

The Operator Metric

Track the Ambulatory Specialty Model payment swing: up to 9 percent of every Medicare Part B claim, positive or negative, tied to a heart-failure quality score. Once performance-based payment adjustments begin in 2029, cardiologists correctly included in the Ambulatory Specialty Model face an adjustment ranging from negative 9 percent to positive 9 percent applied to all of their Medicare Part B claims, not just heart-failure-related ones, based on cost, quality, and improvement-activity scoring. For the roughly 2,100-cardiologist cohort that remains once the misclassified 500 are removed, that swing is the single number that turns this from a reporting exercise into a practice-economics question, and 2026 is the last full year to build the workflow before scoring starts. Confidence: High on the published swing range; Low on the exact cohort size until CMS finalizes corrections. CMS Ambulatory Specialty Model page.